US 12,492,253 B1
Anti-human C5 antibodies
Aaron Keith Chamberlain, Pasadena, CA (US); Bassil Dahiyat, Altadena, CA (US); John R. Desjarlais, Pasadena, CA (US); Sher Bahadur Karki, Santa Monica, CA (US); and Gregory Alan Lazar, Indianapolis, IN (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on May 23, 2025, as Appl. No. 19/218,154.
Application 12/697,933 is a division of application No. 12/341,769, filed on Dec. 22, 2008, granted, now 8,367,805, issued on Feb. 5, 2013.
Application 19/218,154 is a continuation in part of application No. 18/810,362, filed on Aug. 20, 2024, granted, now 12,398,207.
Application 19/218,154 is a continuation in part of application No. 18/744,537, filed on Jun. 14, 2024.
Application 18/810,362 is a continuation of application No. 17/746,226, filed on May 17, 2022, abandoned.
Application 17/746,226 is a continuation of application No. 16/803,690, filed on Feb. 27, 2020, abandoned.
Application 16/803,690 is a continuation of application No. 16/439,575, filed on Jun. 12, 2019, abandoned.
Application 16/439,575 is a continuation of application No. 14/459,160, filed on Aug. 13, 2014, granted, now 10,336,818, issued on Jul. 2, 2019.
Application 14/459,160 is a continuation of application No. 12/697,933, filed on Feb. 1, 2010, granted, now 8,852,586, issued on Oct. 7, 2014.
Claims priority of provisional application 61/099,178, filed on Sep. 22, 2008.
Claims priority of provisional application 61/079,779, filed on Jul. 10, 2008.
Claims priority of provisional application 61/050,172, filed on May 2, 2008.
Claims priority of provisional application 61/046,353, filed on Apr. 18, 2008.
Claims priority of provisional application 61/031,353, filed on Feb. 25, 2008.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 16/18 (2013.01); C07K 2317/52 (2013.01); C07K 2317/94 (2013.01)] 1 Claim
 
1. An antibody comprising:
a) a means for binding human C5; and
b) an Fc domain comprising amino acid substitutions M428L/N434S as compared to a human Fc polypeptide, wherein numbering is according to EU numbering.